News

Data from a trial named IMPACT 2 served as the primary basis for the approval. In the trial, significant improvements in both American College of Rheumatology and psoriasis

The results suggest a role for LINGO-1 in central nervous system (CNS) repair which could lead to potential pathways for treating multiple sclerosis (MS) and other demyelinating diseases.

Results from two new investigational phase III clinical trials showed that oral Hycamtin (topotecan hydrochloride) was clinically active in both small cell lung cancer (SCLC) and non-small cell

The study results form part of an ongoing dual-clinical trial program, named GINEST, evaluating the effectiveness of Gemzar in combination with other leading chemotherapy agents in the treatment

Trials include those conducted in children with solid tumors and in adults with advanced hormone-refractory prostate cancer, advanced gastrointestinal (GI) cancer and small cell lung cancer (SCLC). The

The preliminary data show patients with recurrent glioblastoma multiforme, a form of primary brain cancer, experienced a significant tumor response rate with minimal side effects when treated with

The results demonstrate that Albuferon (albumin-interferon alpha) exhibits more antiviral activity at clinically achieved serum levels than standard interferon alpha or the modified interferons, Roche’s Pegasys (peginterferon alfa-2a)

Omeprazole belongs to a class of proton-pump inhibitors used in the treatment of acid-related gastrointestinal disorders. The product is marketed by Astra Zeneca in Europe under the trade

Lunesta is the first and only sleep aid approved by the FDA for long-term use. Results from two analyses designed to assess potential pharmacoeconomic benefits associated with the